3 results match your criteria: "USA. Electronic address: jchambers@tuftsmedicalcenter.org.[Affiliation]"
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan Drugs.
Value Health
December 2024
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA. Electronic address:
Article Synopsis
- The study evaluates ultraorphan drugs, which are treatments for very rare diseases, focusing on their health benefits, costs, and cost-effectiveness compared to drugs for more common illnesses.
- It analyzed FDA-approved drugs from 1999 to 2019, determining incremental health gains in quality-adjusted life-years (QALYs) and costs, excluding studies funded by manufacturers for objectivity.
- The findings reveal that ultraorphan drugs provide greater health benefits and higher costs compared to both nonorphan and other orphan drugs, leading to much higher incremental cost-effectiveness ratios (ICERs).
A Review of Empirical Analyses of Disinvestment Initiatives.
Value Health
July 2017
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Background: Disinvesting in low-value health care services provides opportunities for investment in higher value care and thus an increase in health care efficiency.
Objectives: To identify international experience with disinvestment initiatives and to review empirical analyses of disinvestment initiatives.
Methods: We performed a literature search using the PubMed database to identify international experience with disinvestment initiatives.
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment).
Health Policy
February 2015
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Boston Scientific, Marlborough, MA, USA. Electronic address:
Context: Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services.
View Article and Find Full Text PDF